Literature DB >> 7107895

Sensitization to low dose 5-fluorouracil. Subsequent enhancement of its systemic antitumor effect in the rat.

R E Falk, M Hardy, L Makowka, J Teodorczyk-Injeyan, J A Falk.   

Abstract

This report describes a novel method of immunochemotherapy; the active immunization to the drug 5-fluorouracil (5-FU) with enhanced antitumor activity resulting from its subsequent systemic administration. Two metastasizing carcinomas in the Fischer strain (F344) rat have been used: a chemically induced bladder carcinoma (FBCa) and a spontaneous mammary adenocarcinoma (MACa). Both tumors grow rapidly and result in 100% mortality within 10 wk of implantation. Neither tumor is sensitive to systemic 5-FU alone. Intradermal sensitization to 5-FU before FBCa tumor implantation, followed by 5-FU administered systemically, resulted in significant tumor regression and improvement in survival with eradication of all tumor and cure in 20% of animals. A similar antitumor effect was observed with the MACa. A comparable drug effect was observed when methotrexate sensitization was given before FBCa implantation followed by systemic MTX. Specificity to the sensitizing drug was demonstrated by the lack of effect of sensitization with either 5-FU or MTX unless followed by systemic therapy with the requisite sensitizing agent. Sensitization to 5-FU has also been assessed after FBCa implantation followed by resection of the local tumor. Resection was performed after distant tumor metastases had occurred, and was followed by systemic 5-FU therapy. Whereas tumor resection alone failed to cure any animal, sensitization to 5-FU increased cure rate fourfold over animals receiving systemic 5-FU alone. Antibody to 5-FU in the sera of sensitized animals has been suggested by an immunoenzymatic staining technique and its specificity confirmed in a radioimmunoassay. It is postulated that a combination of the systemic agent and the antibody elicited to it by sensitization produces the significant antitumor effect observed. The antitumor effect observed with this new approach to immunochemotherapy warrants further experimental and clinical study.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107895      PMCID: PMC370257          DOI: 10.1172/jci110648

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

Review 1.  EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.

Authors:  C HEIDELBERGER; F J ANSFIELD
Journal:  Cancer Res       Date:  1963-09       Impact factor: 12.701

2.  Studies on fluorinated pyrimidines. VIII. Further biochemical and metabolic investigations.

Authors:  E HARBERS; N K CHAUDHURI; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1959-05       Impact factor: 5.157

3.  Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14.

Authors:  K L MUKHERJEE; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1960-02       Impact factor: 5.157

4.  PYRIMIDINE-SPECIFIC ANTIBODIES WHICH REACT WITH DEOXYRIBONUCLEIC ACID (DNA).

Authors:  S W Tanenbaum; S M Beiser
Journal:  Proc Natl Acad Sci U S A       Date:  1963-05       Impact factor: 11.205

5.  THE MODE OF ACTION OF 5-FLUOROURACIL AND ITS DERIVATIVES.

Authors:  S S Cohen; J G Flaks; H D Barner; M R Loeb; J Lichtenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1958-10-15       Impact factor: 11.205

6.  Use of 5-fluorouracil in disseminated solid neoplasms.

Authors:  D B ROCHLIN; J SHINER; E LANGDON; R OTTOMAN
Journal:  Ann Surg       Date:  1962-07       Impact factor: 12.969

7.  Radioimmunoassay of prostaglandins, angiotensin, digoxin, morphine and adenosine-3',5'-cyclic-monophosphate with nitrocellulose membranes.

Authors:  H Gershman; E Powers; L Levine; H Van Vunakis
Journal:  Prostaglandins       Date:  1972-05

Review 8.  Immunosuppressive drugs.

Authors:  T Makinodan; G W Santos; R P Quinn
Journal:  Pharmacol Rev       Date:  1970-06       Impact factor: 25.468

9.  Protein-methotrexate-IgG complexes in the serum of patients receiving high-dose antifolate therapy.

Authors:  M da Costa; W Isacoff; S P Rothenberg; M P Iqbal
Journal:  Cancer       Date:  1980-08-01       Impact factor: 6.860

10.  The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique.

Authors:  R C Graham; M J Karnovsky
Journal:  J Histochem Cytochem       Date:  1966-04       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.